Ovid Therapeutics Inc (NASDAQ:OVID) Short Interest Up 5.8% in January

Share on StockTwits

Ovid Therapeutics Inc (NASDAQ:OVID) was the target of a significant increase in short interest in the month of January. As of January 31st, there was short interest totalling 858,500 shares, an increase of 5.8% from the January 15th total of 811,800 shares. Based on an average trading volume of 727,000 shares, the days-to-cover ratio is presently 1.2 days. Approximately 4.0% of the company’s shares are sold short.

Hedge funds have recently modified their holdings of the stock. Vanguard Group Inc. lifted its stake in shares of Ovid Therapeutics by 67.8% during the second quarter. Vanguard Group Inc. now owns 1,097,614 shares of the company’s stock worth $2,030,000 after buying an additional 443,490 shares during the period. Commonwealth Equity Services LLC acquired a new position in Ovid Therapeutics during the third quarter valued at $56,000. Virtu Financial LLC acquired a new position in Ovid Therapeutics during the third quarter valued at $80,000. Alpine Global Management LLC acquired a new position in Ovid Therapeutics during the fourth quarter valued at $69,000. Finally, Assenagon Asset Management S.A. acquired a new position in Ovid Therapeutics during the fourth quarter valued at $274,000. 17.34% of the stock is currently owned by institutional investors.

A number of brokerages have recently commented on OVID. William Blair reaffirmed a “buy” rating on shares of Ovid Therapeutics in a research report on Friday, November 22nd. Zacks Investment Research raised shares of Ovid Therapeutics from a “hold” rating to a “buy” rating and set a $4.75 target price on the stock in a research report on Friday. ValuEngine lowered shares of Ovid Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, February 1st. Finally, Cowen reaffirmed a “buy” rating on shares of Ovid Therapeutics in a research report on Monday, November 11th. One research analyst has rated the stock with a sell rating and eight have given a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average price target of $13.13.

Shares of NASDAQ:OVID opened at $3.82 on Friday. The firm has a market cap of $208.00 million, a PE ratio of -2.18 and a beta of 2.85. The firm’s 50 day simple moving average is $3.88 and its 200-day simple moving average is $3.00. Ovid Therapeutics has a one year low of $1.53 and a one year high of $5.24. The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.78 and a current ratio of 3.78.

Ovid Therapeutics Company Profile

Ovid Therapeutics Inc, a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which has completed Phase II clinical trial for adults with angelman syndrome; and Phase I clinical trial for adolescents with angelman syndrome or fragile X syndrome.

Read More: Debt-To-Equity Ratio

Receive News & Ratings for Ovid Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ovid Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Riot Blockchain Inc  Given $3.50 Average Target Price by Brokerages
Riot Blockchain Inc Given $3.50 Average Target Price by Brokerages
Todd Pendleton Sells 60,958 Shares of Dolby Laboratories, Inc.  Stock
Todd Pendleton Sells 60,958 Shares of Dolby Laboratories, Inc. Stock
Jeffrey A. Wilke Sells 3,475 Shares of Amazon.com, Inc.  Stock
Jeffrey A. Wilke Sells 3,475 Shares of Amazon.com, Inc. Stock
Insider Selling: Kinder Morgan Inc  Director Sells 309,370 Shares of Stock
Insider Selling: Kinder Morgan Inc Director Sells 309,370 Shares of Stock
Insider Selling: Cadence Design Systems Inc  VP Sells 60,000 Shares of Stock
Insider Selling: Cadence Design Systems Inc VP Sells 60,000 Shares of Stock
C James Koch Sells 10,000 Shares of Boston Beer Company Inc  Stock
C James Koch Sells 10,000 Shares of Boston Beer Company Inc Stock


 
© 2006-2020 Zolmax.